The antibody is directed against the alpha chain of human MHC class II antigens.
| Institute |
|---|
| Medical Research Council |
| Cat. #: | 156595 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Immunology |
| Application: | WB |
| Target: | Human MHC Class II alpha chain |
| Reactivity: | Human |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | The antibody is directed against the alpha chain of human MHC class II antigens. The antibody is poorly reactive with cell surface MHC antigens, but shows excellent reactivity against alpha chains by Western blotting. |
|---|---|
| Conjugation: | Unconjugated |
| Immunogen: | Daudi Burkitt lymphoma cells |
| Myeloma used: | NS1 |
| Target background: | The antibody is directed against the alpha chain of human MHC class II antigens. The antibody is poorly reactive with cell surface MHC antigens, but shows excellent reactivity against alpha chains by Western blotting. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Guy et al. 1982. Eur J Immunol. 12(11):942-8. PMID: 6185348. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.